See more : Bellerophon Therapeutics, Inc. (BLPH) Income Statement Analysis – Financial Results
Complete financial analysis of Tempest Therapeutics, Inc. (TPST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tempest Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Daiho Corporation (1822.T) Income Statement Analysis – Financial Results
- Chuo Gyorui Co., Ltd. (8030.T) Income Statement Analysis – Financial Results
- GRANDTOP YONGXING GROUP CO LTD (601033.SS) Income Statement Analysis – Financial Results
- Urb-it AB (publ) (URBIT.ST) Income Statement Analysis – Financial Results
- i-Tail Corporation Public Company Limited (ITC.BK) Income Statement Analysis – Financial Results
Tempest Therapeutics, Inc. (TPST)
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 295.00K | 653.00K | 277.00K | 9.74M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 381.00K | 1.81M | 1.27M | 815.00K | 1.05M | 32.00K | 28.00K | 5.40M | 2.25M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -381.00K | -1.81M | -1.27M | -815.00K | -1.05M | -32.00K | 267.00K | -4.75M | -1.97M | 9.74M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 90.51% | -727.11% | -711.91% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.50M | 22.53M | 17.17M | 14.39M | 27.84M | 14.43M | 14.53M | 21.64M | 18.43M | 21.78M | 15.80M | 6.32M | 1.17M |
| General & Administrative | 11.66M | 12.11M | 9.82M | 4.91M | 5.51M | 12.45M | 27.74M | 49.22M | 51.59M | 26.15M | 13.33M | 7.21M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 16.50M | -3.79M | -21.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.66M | 12.11M | 9.82M | 4.91M | 16.50M | 8.66M | 5.93M | 49.22M | 51.59M | 26.15M | 13.33M | 7.21M | 1.45M |
| Other Expenses | 0.00 | 549.00K | -34.00K | 0.00 | 0.00 | 0.00 | 4.03M | 5.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.16M | 34.64M | 26.99M | 19.30M | 44.35M | 23.08M | 20.45M | 70.86M | 70.03M | 47.93M | 29.13M | 13.53M | 2.62M |
| Cost & Expenses | 29.16M | 34.64M | 26.99M | 19.30M | 45.40M | 23.12M | 20.48M | 76.27M | 72.28M | 47.93M | 29.13M | 13.53M | 2.62M |
| Interest Income | 1.12M | 549.00K | 1.28K | 90.00K | 264.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.00K | 0.00 |
| Interest Expense | 1.45M | 1.62M | 1.28M | 0.00 | 0.00 | 134.00K | 0.00 | 659.00K | 436.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 381.00K | 1.81M | 1.27M | 815.00K | 1.05M | 32.00K | 28.00K | 2.24M | 1.29M | 450.00K | 231.00K | 0.00 | 0.00 |
| EBITDA | -28.78M | -32.28M | -25.72M | -18.39M | -43.52M | -27.01M | -84.27M | -79.82M | -71.86M | -49.07M | -28.81M | -13.53M | -2.62M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,933.56% | -11,236.45% | -25,528.16% | -504.06% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.16M | -34.64M | -26.99M | -19.30M | -45.40M | -23.12M | -20.48M | -75.61M | -72.00M | -47.93M | -29.13M | -13.53M | -2.62M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,943.05% | -11,579.17% | -25,992.42% | -492.38% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -334.00K | -1.07M | -1.32M | 90.00K | -21.19M | -4.06M | -64.10M | -1.05M | -1.15M | -1.59M | 90.00K | 19.00K | 0.00 |
| Income Before Tax | -29.49M | -35.71M | -28.30M | -19.21M | -44.57M | -27.18M | -84.59M | -82.06M | -73.14M | -49.52M | -29.04M | -13.51M | -2.62M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,673.22% | -12,566.46% | -26,405.78% | -508.68% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.07M | 1.25M | -90.00K | 1.00K | -169.00K | 67.00K | 201.00K | 75.00K | -1.59M | 90.00K | 0.00 | 0.00 |
| Net Income | -29.49M | -36.78M | -29.55M | -19.12M | -44.57M | -27.19M | -84.58M | -82.26M | -73.22M | -49.52M | -29.04M | -13.51M | -2.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,670.51% | -12,597.24% | -26,432.85% | -508.68% | 0.00% | 0.00% | 0.00% |
| EPS | -1.91 | -3.18 | -7.80 | -612.56 | -48.77 | -263.65 | -72.41K | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 | 0.00 |
| EPS Diluted | -1.91 | -3.18 | -7.80 | -612.56 | -48.77 | -263.65 | -72.41K | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 | 0.00 |
| Weighted Avg Shares Out | 15.42M | 11.55M | 3.79M | 31.21K | 913.78K | 103.14K | 1.17K | 142.88K | 120.38K | 100.65K | 100.65K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 15.42M | 11.55M | 3.79M | 31.21K | 913.78K | 103.14K | 1.17K | 142.88K | 120.38K | 100.65K | 100.65K | 0.00 | 0.00 |
Tempest Reports Year End 2023 Financial Results and Provides Business Update
BRISBANE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the year ended 2023 and provided a corporate update.
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors' and officers' possible violations of state laws. If you own Tempest Therapeutics stock, would like to learn...
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that the Compensation Committee of the Company's Board of Directors granted...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that on January 3, 2024 the Compensation Committee of the Company's...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that the Compensation Committee of the Company's Board of Directors granted...
Penny Stocks To Buy? 5 To Watch Right Now
Penny stocks refer to shares of small or micro-cap companies that trade for less than $5 per share. What cheap stocks lack in size and stability, they can potentially make up for in rapid price changes and explosive short-term gains.
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
BRISBANE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will participate in a fireside chat at the 35th...
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
BRISBANE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the third quarter ended September 30, 2023 and...
The Secrets Behind a 4000% Biotech Stock Surge
Remarkably, the stock did not have fundamentally changing news. It did not rocket higher on breaking news that would typically be associated with the whopping gains it experienced.
Source: https://incomestatements.info
Category: Stock Reports